65 filings
Page 2 of 4
8-K
bij hoo5fdsr
15 Sep 21
Departure of Directors or Certain Officers
8:10am
8-K
cjuc0x
5 Aug 21
Jounce Therapeutics Reports Second Quarter 2021 Financial Results
6:37am
8-K
zd8k 5575
23 Jun 21
Submission of Matters to a Vote of Security Holders
4:42pm
8-K
8slz4v8qg19ldqv rt1
4 May 21
Jounce Therapeutics Reports First Quarter 2021 Financial Results
7:09am
8-K
tae tw9vp39m6cw
10 Mar 21
Jounce Therapeutics Announces Proposed Offering of Common Stock
4:48pm
8-K
v7bd 89fxihe1zjsqdy
25 Feb 21
Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
6:39am
8-K
zprijm6hnesozq
12 Feb 21
Departure of Directors or Certain Officers
8:14am
8-K
2i30hcycnn9lfo
11 Jan 21
Results of Operations and Financial Condition
6:11am
8-K
xwn3se6jbio5
6 Nov 20
Jounce Therapeutics Reports Third Quarter 2020 Financial Results
7:11am
8-K
hq36 omdk9paxb0a492
2 Nov 20
Jounce Therapeutics Announces Update on Vopratelimab Program
7:04am
8-K
natgu7ckvo7fxko2sdn
1 Sep 20
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program
8:38am
8-K
swwcb4ht 38xmuhy1nha
7 Aug 20
Jounce Therapeutics Reports Second Quarter 2020 Financial Results
6:48am
8-K
qge1d
29 Jun 20
Submission of Matters to a Vote of Security Holders
12:00am
8-K
5dw c248x9yf
4 Jun 20
Entry into a Material Definitive Agreement
8:07am
8-K
wff3h 9t5c
6 May 20
Jounce Therapeutics Reports First Quarter 2020 Financial Results
7:15am
8-K
pe5wo5yji 2j6s
7 Apr 20
Regulation FD Disclosure
7:55am
8-K
476pbca1l
27 Feb 20
Jounce Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
7:15am
8-K
1rttw d9e
23 Jan 20
Departure of Directors or Certain Officers
8:05am
8-K
z9szr5xm b8vz
13 Jan 20
Results of Operations and Financial Condition
8:01am
8-K
vark0e k36q
17 Dec 19
Entry into a Material Definitive Agreement
5:00pm